Revvity Q1 adj EPS $1.06 beats $1.01 YoY; revenue $711M +7%; plans China IDX divestiture

REVVITY, INC.

2026-Q1 EPS reported $0.36 revenue$711,118,000

Q1 GAAP EPS $0.37 vs $0.35 YoY; adjusted EPS $1.06 vs $1.01; revenue $711M (+7% YoY).
Pro forma (ex-China IDX) revenue $687M, adj EPS $1.04 vs $0.95 YoY.
Signed LOI to sell China Immunodiagnostics business for up to $200M; expects close by 2027.
China IDX represented ~6% of FY2025 total revenue; definitive agreement expected Q2 2026.
Full-year 2026 guidance updated on pro forma basis; management to discuss on call.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REVVITY, INC. reported first quarter ended April 5, 2026 results: revenue $711 million, EPS $0.37.

Period: first quarter ended April 5, 2026
Revenue: $711 million
EPS: $0.37
Result: reported results

Exact text from the filing

OR IMMEDIATE RELEASE May 5, 2026 Revvity Announces Financial Results for the First Quarter of 2026 • Revenue of $711 million; pro forma revenue of $687 million; 7% revenue growth; 3% organic gro wth; 6% pro forma organic growth • GAAP EPS from continuing operations of $0.37 ; adjusted EPS from continuing operations of $1.06 ; GAAP pro forma EPS from continuing operations of $0.40; pro forma adjusted EPS from continuing operations of $1.04 • Announces intention to divest China Immunodiagnostics business • Updates full year 2026 guidance WALTHAM, Mass.

View on SEC.gov

Browse all earnings releases →

REVVITY, INC. filing history →

Source: SEC EDGAR

accession 0000031791-26-000016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.